Strictly Business
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Something to think about decent sized orders going in after hours past few days.
Got some action after hours at double zero 98. Chart would have been setup perfectly tomorrow. I guess they want to keep it down for a bit longer
Greetings Cali... VTEQ yes very interesting comapny with a lot going on behind the scenes. Did you grab yourself a started today under .01 Chart rounding bottom!!!
VTEQ - Bottomed & FDA cleared!!!
DELRAY BEACH, Fla., March 12, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, and Establishment Labs, S.A. ("EL") announced today that The Hospital Group, the largest provider of cosmetic surgery in the United Kingdom ("UK"), now offers EL's Motiva Implant Matrix(R) breast implants with VeriTeQ's Q Inside Safety Technology(TM) to patients choosing to undergo breast augmentation. The Hospital Group operates a network of more than 20 clinics around the UK and Ireland.
Q Inside Safety Technology(TM) is an FDA cleared micro-transponder technology that acts as an electronic serial number enabling physicians and patients to access a secure, online database to retrieve implant-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the device manufacturer. Q Inside Safety Technology(TM) may also provide an extra level of protection to the patient in the event of a recall or other safety event.
http://finance.yahoo.com/news/largest-provider-cosmetic-surgery-uk-143155051.html
VTEQ - Bottomed & FDA cleared
DELRAY BEACH, Fla., March 12, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, and Establishment Labs, S.A. ("EL") announced today that The Hospital Group, the largest provider of cosmetic surgery in the United Kingdom ("UK"), now offers EL's Motiva Implant Matrix(R) breast implants with VeriTeQ's Q Inside Safety Technology(TM) to patients choosing to undergo breast augmentation. The Hospital Group operates a network of more than 20 clinics around the UK and Ireland.
Q Inside Safety Technology(TM) is an FDA cleared micro-transponder technology that acts as an electronic serial number enabling physicians and patients to access a secure, online database to retrieve implant-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the device manufacturer. Q Inside Safety Technology(TM) may also provide an extra level of protection to the patient in the event of a recall or other safety event.
http://finance.yahoo.com/news/largest-provider-cosmetic-surgery-uk-143155051.html
VTEQ - Bottomed & FDA cleared
DELRAY BEACH, Fla., March 12, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, and Establishment Labs, S.A. ("EL") announced today that The Hospital Group, the largest provider of cosmetic surgery in the United Kingdom ("UK"), now offers EL's Motiva Implant Matrix(R) breast implants with VeriTeQ's Q Inside Safety Technology(TM) to patients choosing to undergo breast augmentation. The Hospital Group operates a network of more than 20 clinics around the UK and Ireland.
Q Inside Safety Technology(TM) is an FDA cleared micro-transponder technology that acts as an electronic serial number enabling physicians and patients to access a secure, online database to retrieve implant-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the device manufacturer. Q Inside Safety Technology(TM) may also provide an extra level of protection to the patient in the event of a recall or other safety event.
http://finance.yahoo.com/news/largest-provider-cosmetic-surgery-uk-143155051.html
Professional corporations
The letters "PC" after a business's name stand for professional corporation. This special corporate status applies to licensed professions such as medicine, law and accounting. Professional corporations enjoy some, but not all, of the same liability protections as general corporations
Dont count them out yet. Iam wishing the next PR or 2 announcing a Joint Venture agreement!!
Perhaps even more interesting, is the fact that we have yet to hear about Mentor or Allergen on this matter. These companies together represent 81% of the breast implant market, and currently have no competing technologies in development. Knowing the FDA’s new requirements, as well as the cost
associated with developing a technology like VeriTeQ’s, it would seem logical that VeriTeQ could begin to receive interest from these major players in the implantation market.
We note that the press release from February 12th, 2015 is a very interesting development for VeriTeQ Corp.
Essentially, the term sheet the company has executed gives Establishment Labs, S.A. “EL” the option to exclusively license VeriTeQ’s intellectual property, safety data test and FDA file reference, and business opportunities related to its Q Inside Safety Technology for the breast implant market for an upfront license fee of $1.75 million with a 24-month option to purchase VeriTeQ’s Q Inside Safety Technology business for the breast implant market for $10 million, minus the license fee.
VTEQ - Completed.
DELRAY BEACH, Fla., Feb. 10, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation (OTC Markets:VTEQ) ("VeriTeQ" or the "Company"), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that its Board of Directors and FINRA have approved a reverse split of the Company's common stock at a ratio of 1-for-1000, commencing at the open of trading on February 11, 2015
http://finance.yahoo.com/news/veriteq-corporation-announces-reverse-stock-133000407.html
MUST READ DD >> VeriTeQ Corporation (VTEQ), the Food And Drug Administration (FDA) has approved VeriTeQ’s (VTEQ) cutting edge technologies. The company is now engaged in there commercial launch generating revenues that are projected to grow at explosive rates, quarter over quarter, year over year!
ORIGINAL POST:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110388365
Highlights:
-VeriTeQ (VTEQ) offers the world’s first FDA cleared RFID microchip technology that can be used to identify implantable medical devices,
-The FDA has mandated that starting September 2014 a national system be in place to identify medical devices during their distribution and use.
-What this all means is that VeriTeQ will have the government mandating that other companies use their product in order to be in FDA compliance. How great is that, estimates are that VeriTeQ will generate $239 million in future revenues thanks to it’s leading first-to-market world’s first FDA cleared RFIDmicrochip technology!
-VeriTeQ’s (VTEQ) FDA cleared dosimeter technologies for use in radiation therapy treatment.
- VeriTeQ’s “One Dose” external sensor is the only wireless pre-calbrated sensor on the market that can instantly provide measurement of radiation of dose delivered at skin level. VeriTeQ’s internal FDA cleared sensor is the only one on the market that confirms radiation dose directly to the tumor. The FDA has approved it for use in prostrate and breast cancer radiotherapy. Revenues generated from VeriTeQ’s FDA cleared dosimeter technologies for use in radiation therapy treatment are projected to be larger than those for it’s RFID microchip technology.
Yet VeriTeQ’s (VTEQ) share price is trading currently at historic lows in the sub penny range, under the radar! Now is the time to buy VeriTeQ (VTEQ), at this level huge percentage gains are not only possible but very likely as huge revenues flow in and grow at explosive rates, quarter over quarter, year over year!
Lets examine VeriTeQ’s (VTEQ) FDA approved innovative technologies and then be astounded that this stock is trading sub-penny, it should and likely will be trading in the multiple dollar range in the near future as the market catches up!
VeriTeQ’s (VTEQ) FDA cleared, radio frequency identification (RFID) solutions
VeriTeQ’s (VTEQ) FDA cleared, radio frequency identification (RFID) solutions identify implantable medical devices. This acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data from the medical device manufacturer. VeriTeQ offers the world’s first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care.
The [B]FDA has mandated that starting September 2014 a national system be in place to identify medical devices during their distribution and use. This unique identification system known as (UDI) will be used for multiple functions including in the event of adverse events or recalls to facilitate the identification of the implanted device, more efficiently target recalls and reduce the chance that patients receive devices that have been identified as problematic.
What this all means is that VeriTeQ will have the government mandating that other companies use their product in order to be in FDA compliance. How great is that, estimates are that VeriTeQ will generate $239 million in future revenues thanks to it’s leading first-to-marketworld’s first FDA cleared RFID microchip technology!
To summarize, VeriTeQ will sell RFID microchips that will be inserted into breast implants, artificial joints etc that can then be scanned by medical personnel using VeriTeQ’s hand held scanner. VeriTech generates revenues on the RFID microchips and their hand held scanner!
According to the International Society of Aesthetic Plastic Surgery, the number of breast augmentation procedures performed worldwide in 2011 exceeded 1.2 million.
VeriTeQ’s (VTEQ) FDA cleared dosimeter technologies for use in radiation therapy treatment.
VeriTeQ’s dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. Accurate and timely data on radiation doses delivered to patients is increasingly recognized as critical to patient safety, quality assurance and risk management. Instances of radiation overdose involving hundreds of patients have occurred at prominent hospitals across the country. VeriTeQ’s dosimeter technologies provide radiation oncologists a valuable tool to help ensure patient safety and improve the overall quality of care.
VeriTeQ’s “One Dose” external sensor is the only wireless pre-calbrated sensor on the market that can instantly provide measurement of radiation of dose delivered at skin level.
VeriTeQ’s internal FDA cleared sensor is the only one on the market that confirms radiation dose directly to the tumor. The FDA has approved it for use in prostrate and breast cancer radiotherapy. VeriTeQ future goals could include it being FDA approved for colorectal ,pancreatic and lung tumor types.
The revenue potential here is massive and could dwarf the huge revenues projected from VeriTeQ’s RFID microchip technology. VeriTeQ’s initial target market is the over 1 million patients receiving external beam radiation therapy in the United States alone and potential revenues from internal radiation measurement and new FDA treatment pathways.
Some of the most recent exciting developments for VeriTeQ (VTEQ)
(This is an exciting growing company with a product that has been mandated for use by the FDA, innovative, transparent and now insanely undervalued trading in the sub penny range. Now is the time to buy with blue skies ahead!))
November 24th 2014: VeriTeQ (VTEQ)announced that in conjunction with its customer Establishment Labs it will initiate development of a pressure-sensing microtransponder to be used in tissue expanders for breast reconstruction and tissue expansion.
November 5th 2014: VeriTeQ (VTEQ) announced new financing with New York investment firm Magna for up to $450,000.
October 15th 2014: VeriTeQ (VTEQ) announced that the Company and its breast implant customer, Establishment Labs planned to host a physician conference in Salzburg, Austria.
October 9th 2014: VeriTeQ (VTEQ) announced today that it has entered an agreement providing an exclusive license of multiple patents from North Carolina State University (“NCSU”). VeriTeQ will license 24 patents, which are the foundation for its FDA cleared Q Inside SmartMarker and OneDose products for radiation dosimetry.
September 29th 2014: VeriTeQ (VTEQ) announced today that it has received an order for 100 units of its new Q Inside readers for breast implants
September 18th 2014: VeriTeQ (VTEQ) announced today that it has unveiled two new readers used to identify VeriTeQ’s Q Inside Safety Technology(TM) within implantable medical devices: the Q Inside Reader + and the Q Inside Reader XR +. The new readers are being launched based on demand from the breast implant industry.
September 16th 2014: VeriTeQ (VTEQ) announced today that more than 1,000 women worldwide have now received Motiva Implant Matrix® breast implants with VeriTeQ’s Q Inside Safety Technology™. Motiva Implant Matrix® breast implants, manufactured by Establishment Labs S.A. (“EL”), featuring VeriTeQ’s Q Inside Safety Technology™ can be safely and accurately identified from outside of the body in a physician’s office
August 26th 2014: VeriTeQ (VTEQ) announced today that it will host a conference call on Wednesday, September 3, 2014, at 10 a.m. ET, to update investors on the business and other recent events.
July 9th 2014: VeriTeQ (VTEQ) announced today that it received an order for 10,200 Q Inside Safety Technology™ radio frequency identification microtransponders from breast implant customer Establishment Labs (“EL”). EL will use Q Inside Safety Technology microtransponders for the continued commercialization of its Motiva Implant Matrix® breast implants throughout Europe.
More interesting information on why now is the time to buy VeriTeQ (VTEQ)
VeriTeQ’s Chairman and CEO, Scott R. Silverman “Now that the commercial launch of our products is underway and we are becoming more active in the capital
markets with a goal of a future up-listing”
Flying so low under the radar, It only went public in July 2013 and is completely oversold, trading at historic lows with the share price now incredibly in the sub-penny range.
In February 2014 Zacks Investment Research (“Zacks”) initiated coverage of the Company with an outperform rating, meaning that they anticipated it will outperform
other stocks in it’s sector, now that is essentially a BUY rating!
VeriTeQ is currently working with breast implant manufacturer Establishment Labs, S.A., which markets its Motiva Implant Matrix® breast implants with VeriTeQ’s Q
Inside Safety Technology in the European Union
Establishment Labs has begun the commercial launch of its Motiva Implant Matrix® breast implants with VeriTeQ’s Q Inside Safety Technology in the European Union.
EL’s Motiva Implant Matrix Ergonomix, VelvetSurface PLUS, and SilkSurface PLUS, all with VeriTeQ’s Q Inside Safety Technology, have received CE Mark approval, which enables Establishment Labs to market its Motiva breast implants to patients in 28 countries in the European Union and fast track regulatory approvals in many countries in South America, Middle East and Asia.
VeriTeQ looks to have a break out year in 2015: Core Technology: implantable radio frequency (RF) microchip technology with over 100 Patents, Patent Pendings, and Licensed Applications
Michael Krawitz its Chief Legal and Financial Officer. Mr. Krawitz is a skilled executive with extensive capital markets experience who holds a a juris doctorate from Harvard Law School. Krawitz stated, “VeriTeQ captured my interest with OneDose and related products that allow radiation oncologists to more accurately deliver radiation therapy. It’s a
great example of what VeriTeQ does with all of its products — using technology to give doctors, nurses and patients more accurate information, leading to better
treatment and fewer mistakes. I’m proud to be a part of that. From a business perspective, we believe our products result in better treatment and fewer mistakes,
thereby reducing liability and offering a competitive advantage for hospitals and doctors. I am excited to work again with Scott and our team on this early opportunity to
grow VeriTeQ and participate in its long-term success.”
This write up of VeriTeQ Corporation (VTEQ) contains information from multiple sources including:
VeriTeQ’s (VTEQ) website
http://www.veriteqcorp.com/
Official Press Releases
http://finance.yahoo.com/q/p?s=VTEQ+Press+Releases
A Seeking Alpha article
http://seekingalpha.com/article/1939671-new-mandate-will-help-sell-veriteqs-fda-approved-microchip
Zach’s Investment Research
http://scr.zacks.com/files/doc_coverage/Med-Tech%20-%20Brian%20Marckx/VTEQ/February%2012%202014_VTEQ_Marckx.pdf
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110388365
MUST READ DD >> VeriTeQ Corporation (VTEQ), the Food And Drug Administration (FDA) has approved VeriTeQ’s (VTEQ) cutting edge technologies. The company is now engaged in there commercial launch generating revenues that are projected to grow at explosive rates, quarter over quarter, year over year!
ORIGINAL POST:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110388365
Highlights:
-VeriTeQ (VTEQ) offers the world’s first FDA cleared RFID microchip technology that can be used to identify implantable medical devices,
-The FDA has mandated that starting September 2014 a national system be in place to identify medical devices during their distribution and use.
-What this all means is that VeriTeQ will have the government mandating that other companies use their product in order to be in FDA compliance. How great is that, estimates are that VeriTeQ will generate $239 million in future revenues thanks to it’s leading first-to-market world’s first FDA cleared RFIDmicrochip technology!
-VeriTeQ’s (VTEQ) FDA cleared dosimeter technologies for use in radiation therapy treatment.
- VeriTeQ’s “One Dose” external sensor is the only wireless pre-calbrated sensor on the market that can instantly provide measurement of radiation of dose delivered at skin level. VeriTeQ’s internal FDA cleared sensor is the only one on the market that confirms radiation dose directly to the tumor. The FDA has approved it for use in prostrate and breast cancer radiotherapy. Revenues generated from VeriTeQ’s FDA cleared dosimeter technologies for use in radiation therapy treatment are projected to be larger than those for it’s RFID microchip technology.
Yet VeriTeQ’s (VTEQ) share price is trading currently at historic lows in the sub penny range, under the radar! Now is the time to buy VeriTeQ (VTEQ), at this level huge percentage gains are not only possible but very likely as huge revenues flow in and grow at explosive rates, quarter over quarter, year over year!
Lets examine VeriTeQ’s (VTEQ) FDA approved innovative technologies and then be astounded that this stock is trading sub-penny, it should and likely will be trading in the multiple dollar range in the near future as the market catches up!
VeriTeQ’s (VTEQ) FDA cleared, radio frequency identification (RFID) solutions
VeriTeQ’s (VTEQ) FDA cleared, radio frequency identification (RFID) solutions identify implantable medical devices. This acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data from the medical device manufacturer. VeriTeQ offers the world’s first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care.
The [B]FDA has mandated that starting September 2014 a national system be in place to identify medical devices during their distribution and use. This unique identification system known as (UDI) will be used for multiple functions including in the event of adverse events or recalls to facilitate the identification of the implanted device, more efficiently target recalls and reduce the chance that patients receive devices that have been identified as problematic.
What this all means is that VeriTeQ will have the government mandating that other companies use their product in order to be in FDA compliance. How great is that, estimates are that VeriTeQ will generate $239 million in future revenues thanks to it’s leading first-to-marketworld’s first FDA cleared RFID microchip technology!
To summarize, VeriTeQ will sell RFID microchips that will be inserted into breast implants, artificial joints etc that can then be scanned by medical personnel using VeriTeQ’s hand held scanner. VeriTech generates revenues on the RFID microchips and their hand held scanner!
According to the International Society of Aesthetic Plastic Surgery, the number of breast augmentation procedures performed worldwide in 2011 exceeded 1.2 million.
VeriTeQ’s (VTEQ) FDA cleared dosimeter technologies for use in radiation therapy treatment.
VeriTeQ’s dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. Accurate and timely data on radiation doses delivered to patients is increasingly recognized as critical to patient safety, quality assurance and risk management. Instances of radiation overdose involving hundreds of patients have occurred at prominent hospitals across the country. VeriTeQ’s dosimeter technologies provide radiation oncologists a valuable tool to help ensure patient safety and improve the overall quality of care.
VeriTeQ’s “One Dose” external sensor is the only wireless pre-calbrated sensor on the market that can instantly provide measurement of radiation of dose delivered at skin level.
VeriTeQ’s internal FDA cleared sensor is the only one on the market that confirms radiation dose directly to the tumor. The FDA has approved it for use in prostrate and breast cancer radiotherapy. VeriTeQ future goals could include it being FDA approved for colorectal ,pancreatic and lung tumor types.
The revenue potential here is massive and could dwarf the huge revenues projected from VeriTeQ’s RFID microchip technology. VeriTeQ’s initial target market is the over 1 million patients receiving external beam radiation therapy in the United States alone and potential revenues from internal radiation measurement and new FDA treatment pathways.
Some of the most recent exciting developments for VeriTeQ (VTEQ)
(This is an exciting growing company with a product that has been mandated for use by the FDA, innovative, transparent and now insanely undervalued trading in the sub penny range. Now is the time to buy with blue skies ahead!))
November 24th 2014: VeriTeQ (VTEQ)announced that in conjunction with its customer Establishment Labs it will initiate development of a pressure-sensing microtransponder to be used in tissue expanders for breast reconstruction and tissue expansion.
November 5th 2014: VeriTeQ (VTEQ) announced new financing with New York investment firm Magna for up to $450,000.
October 15th 2014: VeriTeQ (VTEQ) announced that the Company and its breast implant customer, Establishment Labs planned to host a physician conference in Salzburg, Austria.
October 9th 2014: VeriTeQ (VTEQ) announced today that it has entered an agreement providing an exclusive license of multiple patents from North Carolina State University (“NCSU”). VeriTeQ will license 24 patents, which are the foundation for its FDA cleared Q Inside SmartMarker and OneDose products for radiation dosimetry.
September 29th 2014: VeriTeQ (VTEQ) announced today that it has received an order for 100 units of its new Q Inside readers for breast implants
September 18th 2014: VeriTeQ (VTEQ) announced today that it has unveiled two new readers used to identify VeriTeQ’s Q Inside Safety Technology(TM) within implantable medical devices: the Q Inside Reader + and the Q Inside Reader XR +. The new readers are being launched based on demand from the breast implant industry.
September 16th 2014: VeriTeQ (VTEQ) announced today that more than 1,000 women worldwide have now received Motiva Implant Matrix® breast implants with VeriTeQ’s Q Inside Safety Technology™. Motiva Implant Matrix® breast implants, manufactured by Establishment Labs S.A. (“EL”), featuring VeriTeQ’s Q Inside Safety Technology™ can be safely and accurately identified from outside of the body in a physician’s office
August 26th 2014: VeriTeQ (VTEQ) announced today that it will host a conference call on Wednesday, September 3, 2014, at 10 a.m. ET, to update investors on the business and other recent events.
July 9th 2014: VeriTeQ (VTEQ) announced today that it received an order for 10,200 Q Inside Safety Technology™ radio frequency identification microtransponders from breast implant customer Establishment Labs (“EL”). EL will use Q Inside Safety Technology microtransponders for the continued commercialization of its Motiva Implant Matrix® breast implants throughout Europe.
More interesting information on why now is the time to buy VeriTeQ (VTEQ)
VeriTeQ’s Chairman and CEO, Scott R. Silverman “Now that the commercial launch of our products is underway and we are becoming more active in the capital
markets with a goal of a future up-listing”
Flying so low under the radar, It only went public in July 2013 and is completely oversold, trading at historic lows with the share price now incredibly in the sub-penny range.
In February 2014 Zacks Investment Research (“Zacks”) initiated coverage of the Company with an outperform rating, meaning that they anticipated it will outperform
other stocks in it’s sector, now that is essentially a BUY rating!
VeriTeQ is currently working with breast implant manufacturer Establishment Labs, S.A., which markets its Motiva Implant Matrix® breast implants with VeriTeQ’s Q
Inside Safety Technology in the European Union
Establishment Labs has begun the commercial launch of its Motiva Implant Matrix® breast implants with VeriTeQ’s Q Inside Safety Technology in the European Union.
EL’s Motiva Implant Matrix Ergonomix, VelvetSurface PLUS, and SilkSurface PLUS, all with VeriTeQ’s Q Inside Safety Technology, have received CE Mark approval, which enables Establishment Labs to market its Motiva breast implants to patients in 28 countries in the European Union and fast track regulatory approvals in many countries in South America, Middle East and Asia.
VeriTeQ looks to have a break out year in 2015: Core Technology: implantable radio frequency (RF) microchip technology with over 100 Patents, Patent Pendings, and Licensed Applications
Michael Krawitz its Chief Legal and Financial Officer. Mr. Krawitz is a skilled executive with extensive capital markets experience who holds a a juris doctorate from Harvard Law School. Krawitz stated, “VeriTeQ captured my interest with OneDose and related products that allow radiation oncologists to more accurately deliver radiation therapy. It’s a
great example of what VeriTeQ does with all of its products — using technology to give doctors, nurses and patients more accurate information, leading to better
treatment and fewer mistakes. I’m proud to be a part of that. From a business perspective, we believe our products result in better treatment and fewer mistakes,
thereby reducing liability and offering a competitive advantage for hospitals and doctors. I am excited to work again with Scott and our team on this early opportunity to
grow VeriTeQ and participate in its long-term success.”
This write up of VeriTeQ Corporation (VTEQ) contains information from multiple sources including:
VeriTeQ’s (VTEQ) website
http://www.veriteqcorp.com/
Official Press Releases
http://finance.yahoo.com/q/p?s=VTEQ+Press+Releases
A Seeking Alpha article
http://seekingalpha.com/article/1939671-new-mandate-will-help-sell-veriteqs-fda-approved-microchip
Zach’s Investment Research
http://scr.zacks.com/files/doc_coverage/Med-Tech%20-%20Brian%20Marckx/VTEQ/February%2012%202014_VTEQ_Marckx.pdf
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110388365
MUST READ DD >> VeriTeQ Corporation (VTEQ), the Food And Drug Administration (FDA) has approved VeriTeQ’s (VTEQ) cutting edge technologies. The company is now engaged in there commercial launch generating revenues that are projected to grow at explosive rates, quarter over quarter, year over year!
ORIGINAL POST:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110388365
Highlights:
-VeriTeQ (VTEQ) offers the world’s first FDA cleared RFID microchip technology that can be used to identify implantable medical devices,
-The FDA has mandated that starting September 2014 a national system be in place to identify medical devices during their distribution and use.
-What this all means is that VeriTeQ will have the government mandating that other companies use their product in order to be in FDA compliance. How great is that, estimates are that VeriTeQ will generate $239 million in future revenues thanks to it’s leading first-to-market world’s first FDA cleared RFIDmicrochip technology!
-VeriTeQ’s (VTEQ) FDA cleared dosimeter technologies for use in radiation therapy treatment.
- VeriTeQ’s “One Dose” external sensor is the only wireless pre-calbrated sensor on the market that can instantly provide measurement of radiation of dose delivered at skin level. VeriTeQ’s internal FDA cleared sensor is the only one on the market that confirms radiation dose directly to the tumor. The FDA has approved it for use in prostrate and breast cancer radiotherapy. Revenues generated from VeriTeQ’s FDA cleared dosimeter technologies for use in radiation therapy treatment are projected to be larger than those for it’s RFID microchip technology.
Yet VeriTeQ’s (VTEQ) share price is trading currently at historic lows in the sub penny range, under the radar! Now is the time to buy VeriTeQ (VTEQ), at this level huge percentage gains are not only possible but very likely as huge revenues flow in and grow at explosive rates, quarter over quarter, year over year!
Lets examine VeriTeQ’s (VTEQ) FDA approved innovative technologies and then be astounded that this stock is trading sub-penny, it should and likely will be trading in the multiple dollar range in the near future as the market catches up!
VeriTeQ’s (VTEQ) FDA cleared, radio frequency identification (RFID) solutions
VeriTeQ’s (VTEQ) FDA cleared, radio frequency identification (RFID) solutions identify implantable medical devices. This acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data from the medical device manufacturer. VeriTeQ offers the world’s first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care.
The [B]FDA has mandated that starting September 2014 a national system be in place to identify medical devices during their distribution and use. This unique identification system known as (UDI) will be used for multiple functions including in the event of adverse events or recalls to facilitate the identification of the implanted device, more efficiently target recalls and reduce the chance that patients receive devices that have been identified as problematic.
What this all means is that VeriTeQ will have the government mandating that other companies use their product in order to be in FDA compliance. How great is that, estimates are that VeriTeQ will generate $239 million in future revenues thanks to it’s leading first-to-marketworld’s first FDA cleared RFID microchip technology!
To summarize, VeriTeQ will sell RFID microchips that will be inserted into breast implants, artificial joints etc that can then be scanned by medical personnel using VeriTeQ’s hand held scanner. VeriTech generates revenues on the RFID microchips and their hand held scanner!
According to the International Society of Aesthetic Plastic Surgery, the number of breast augmentation procedures performed worldwide in 2011 exceeded 1.2 million.
VeriTeQ’s (VTEQ) FDA cleared dosimeter technologies for use in radiation therapy treatment.
VeriTeQ’s dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. Accurate and timely data on radiation doses delivered to patients is increasingly recognized as critical to patient safety, quality assurance and risk management. Instances of radiation overdose involving hundreds of patients have occurred at prominent hospitals across the country. VeriTeQ’s dosimeter technologies provide radiation oncologists a valuable tool to help ensure patient safety and improve the overall quality of care.
VeriTeQ’s “One Dose” external sensor is the only wireless pre-calbrated sensor on the market that can instantly provide measurement of radiation of dose delivered at skin level.
VeriTeQ’s internal FDA cleared sensor is the only one on the market that confirms radiation dose directly to the tumor. The FDA has approved it for use in prostrate and breast cancer radiotherapy. VeriTeQ future goals could include it being FDA approved for colorectal ,pancreatic and lung tumor types.
The revenue potential here is massive and could dwarf the huge revenues projected from VeriTeQ’s RFID microchip technology. VeriTeQ’s initial target market is the over 1 million patients receiving external beam radiation therapy in the United States alone and potential revenues from internal radiation measurement and new FDA treatment pathways.
Some of the most recent exciting developments for VeriTeQ (VTEQ)
(This is an exciting growing company with a product that has been mandated for use by the FDA, innovative, transparent and now insanely undervalued trading in the sub penny range. Now is the time to buy with blue skies ahead!))
November 24th 2014: VeriTeQ (VTEQ)announced that in conjunction with its customer Establishment Labs it will initiate development of a pressure-sensing microtransponder to be used in tissue expanders for breast reconstruction and tissue expansion.
November 5th 2014: VeriTeQ (VTEQ) announced new financing with New York investment firm Magna for up to $450,000.
October 15th 2014: VeriTeQ (VTEQ) announced that the Company and its breast implant customer, Establishment Labs planned to host a physician conference in Salzburg, Austria.
October 9th 2014: VeriTeQ (VTEQ) announced today that it has entered an agreement providing an exclusive license of multiple patents from North Carolina State University (“NCSU”). VeriTeQ will license 24 patents, which are the foundation for its FDA cleared Q Inside SmartMarker and OneDose products for radiation dosimetry.
September 29th 2014: VeriTeQ (VTEQ) announced today that it has received an order for 100 units of its new Q Inside readers for breast implants
September 18th 2014: VeriTeQ (VTEQ) announced today that it has unveiled two new readers used to identify VeriTeQ’s Q Inside Safety Technology(TM) within implantable medical devices: the Q Inside Reader + and the Q Inside Reader XR +. The new readers are being launched based on demand from the breast implant industry.
September 16th 2014: VeriTeQ (VTEQ) announced today that more than 1,000 women worldwide have now received Motiva Implant Matrix® breast implants with VeriTeQ’s Q Inside Safety Technology™. Motiva Implant Matrix® breast implants, manufactured by Establishment Labs S.A. (“EL”), featuring VeriTeQ’s Q Inside Safety Technology™ can be safely and accurately identified from outside of the body in a physician’s office
August 26th 2014: VeriTeQ (VTEQ) announced today that it will host a conference call on Wednesday, September 3, 2014, at 10 a.m. ET, to update investors on the business and other recent events.
July 9th 2014: VeriTeQ (VTEQ) announced today that it received an order for 10,200 Q Inside Safety Technology™ radio frequency identification microtransponders from breast implant customer Establishment Labs (“EL”). EL will use Q Inside Safety Technology microtransponders for the continued commercialization of its Motiva Implant Matrix® breast implants throughout Europe.
More interesting information on why now is the time to buy VeriTeQ (VTEQ)
VeriTeQ’s Chairman and CEO, Scott R. Silverman “Now that the commercial launch of our products is underway and we are becoming more active in the capital
markets with a goal of a future up-listing”
Flying so low under the radar, It only went public in July 2013 and is completely oversold, trading at historic lows with the share price now incredibly in the sub-penny range.
In February 2014 Zacks Investment Research (“Zacks”) initiated coverage of the Company with an outperform rating, meaning that they anticipated it will outperform
other stocks in it’s sector, now that is essentially a BUY rating!
VeriTeQ is currently working with breast implant manufacturer Establishment Labs, S.A., which markets its Motiva Implant Matrix® breast implants with VeriTeQ’s Q
Inside Safety Technology in the European Union
Establishment Labs has begun the commercial launch of its Motiva Implant Matrix® breast implants with VeriTeQ’s Q Inside Safety Technology in the European Union.
EL’s Motiva Implant Matrix Ergonomix, VelvetSurface PLUS, and SilkSurface PLUS, all with VeriTeQ’s Q Inside Safety Technology, have received CE Mark approval, which enables Establishment Labs to market its Motiva breast implants to patients in 28 countries in the European Union and fast track regulatory approvals in many countries in South America, Middle East and Asia.
VeriTeQ looks to have a break out year in 2015: Core Technology: implantable radio frequency (RF) microchip technology with over 100 Patents, Patent Pendings, and Licensed Applications
Michael Krawitz its Chief Legal and Financial Officer. Mr. Krawitz is a skilled executive with extensive capital markets experience who holds a a juris doctorate from Harvard Law School. Krawitz stated, “VeriTeQ captured my interest with OneDose and related products that allow radiation oncologists to more accurately deliver radiation therapy. It’s a
great example of what VeriTeQ does with all of its products — using technology to give doctors, nurses and patients more accurate information, leading to better
treatment and fewer mistakes. I’m proud to be a part of that. From a business perspective, we believe our products result in better treatment and fewer mistakes,
thereby reducing liability and offering a competitive advantage for hospitals and doctors. I am excited to work again with Scott and our team on this early opportunity to
grow VeriTeQ and participate in its long-term success.”
This write up of VeriTeQ Corporation (VTEQ) contains information from multiple sources including:
VeriTeQ’s (VTEQ) website
http://www.veriteqcorp.com/
Official Press Releases
http://finance.yahoo.com/q/p?s=VTEQ+Press+Releases
A Seeking Alpha article
http://seekingalpha.com/article/1939671-new-mandate-will-help-sell-veriteqs-fda-approved-microchip
Zach’s Investment Research
http://scr.zacks.com/files/doc_coverage/Med-Tech%20-%20Brian%20Marckx/VTEQ/February%2012%202014_VTEQ_Marckx.pdf
Hi Mick...Long time - nice to see you here!
$VTEQ - FDA cleared RFID microtransponder technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time.
There are 2 major takeaways investors should monitor based on this news:
1. The Establishment Labs option essentially values VTEQD's breast implant marker business at $10 Million dollars, with the current market cap around $40k, this would have VeriTeQ severely undervalued by the market.
2. Perhaps even more interesting, is the fact that we have yet to hear about Mentor or Allergen on this matter. These companies together represent 81% of the breast implant market, and currently have no competing technologies in development. Knowing the FDA's new requirements, as well as the cost associated with developing a technology like VeriTeQ's, it would seem logical that VeriTeQ could begin to receive interest from these major players in the implantation market."
http://finance.yahoo.com/news/ticker-research-issues-report-veriteq-213000991.html
Largest Provider of Cosmetic Surgery in the UK Now Offers Motiva Breast Implants With VeriTeQ's Q Inside Safety Technology
DELRAY BEACH, Fla., March 12, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, and Establishment Labs, S.A. ("EL") announced today that The Hospital Group, the largest provider of cosmetic surgery in the United Kingdom ("UK"), now offers EL's Motiva Implant Matrix(R) breast implants with VeriTeQ's Q Inside Safety Technology(TM) to patients choosing to undergo breast augmentation. The Hospital Group operates a network of more than 20 clinics around the UK and Ireland.
http://finance.yahoo.com/news/largest-provider-cosmetic-surgery-uk-143155051.html
There are 2 major takeaways investors should monitor based on this news:
1. The Establishment Labs option essentially values VTEQD's breast implant marker business at $10 Million dollars, with the current market cap around $40k, this would have VeriTeQ severely undervalued by the market.
2. Perhaps even more interesting, is the fact that we have yet to hear about Mentor or Allergen on this matter. These companies together represent 81% of the breast implant market, and currently have no competing technologies in development. Knowing the FDA's new requirements, as well as the cost associated with developing a technology like VeriTeQ's, it would seem logical that VeriTeQ could begin to receive interest from these major players in the implantation market."
$VTEQ - Offers the world's first FDA cleared RFID microtransponder technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time.
There are 2 major takeaways investors should monitor based on this news:
1. The Establishment Labs option essentially values VTEQD's breast implant marker business at $10 Million dollars, with the current market cap around $40k, this would have VeriTeQ severely undervalued by the market.
2. Perhaps even more interesting, is the fact that we have yet to hear about Mentor or Allergen on this matter. These companies together represent 81% of the breast implant market, and currently have no competing technologies in development. Knowing the FDA's new requirements, as well as the cost associated with developing a technology like VeriTeQ's, it would seem logical that VeriTeQ could begin to receive interest from these major players in the implantation market."
http://tickerresearch.com/wp-content/uploads/2015/03/TickerResearch-VTEQD_Research_Report_March_3.pdf
$VTEQ - Offers the world's first FDA cleared RFID microtransponder technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time.
There are 2 major takeaways investors should monitor based on this news:
1. The Establishment Labs option essentially values VTEQD's breast implant marker business at $10 Million dollars, with the current market cap around $40k, this would have VeriTeQ severely undervalued by the market.
2. Perhaps even more interesting, is the fact that we have yet to hear about Mentor or Allergen on this matter. These companies together represent 81% of the breast implant market, and currently have no competing technologies in development. Knowing the FDA's new requirements, as well as the cost associated with developing a technology like VeriTeQ's, it would seem logical that VeriTeQ could begin to receive interest from these major players in the implantation market."
http://tickerresearch.com/wp-content/uploads/2015/03/TickerResearch-VTEQD_Research_Report_March_3.pdf
$VTEQ - Offers the world's first FDA cleared RFID microtransponder technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time.
There are 2 major takeaways investors should monitor based on this news:
1. The Establishment Labs option essentially values VTEQD's breast implant marker business at $10 Million dollars, with the current market cap around $40k, this would have VeriTeQ severely undervalued by the market.
2. Perhaps even more interesting, is the fact that we have yet to hear about Mentor or Allergen on this matter. These companies together represent 81% of the breast implant market, and currently have no competing technologies in development. Knowing the FDA's new requirements, as well as the cost associated with developing a technology like VeriTeQ's, it would seem logical that VeriTeQ could begin to receive interest from these major players in the implantation market."
http://tickerresearch.com/wp-content/uploads/2015/03/TickerResearch-VTEQD_Research_Report_March_3.pdf
$VTEQ - Offers the world's first FDA cleared RFID microtransponder technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time.
There are 2 major takeaways investors should monitor based on this news:
1. The Establishment Labs option essentially values VTEQD's breast implant marker business at $10 Million dollars, with the current market cap around $40k, this would have VeriTeQ severely undervalued by the market.
2. Perhaps even more interesting, is the fact that we have yet to hear about Mentor or Allergen on this matter. These companies together represent 81% of the breast implant market, and currently have no competing technologies in development. Knowing the FDA's new requirements, as well as the cost associated with developing a technology like VeriTeQ's, it would seem logical that VeriTeQ could begin to receive interest from these major players in the implantation market."
http://tickerresearch.com/wp-content/uploads/2015/03/TickerResearch-VTEQD_Research_Report_March_3.pdf
QIT.v ~ acquisition of a 100% interest....
Quinto Real Capital Corporation (TSX VENTURE:QIT) ("Quinto" or the "Company") is pleased to announce the acquisition of a 100% interest in three promising gold and base metal properties in the Schreiber-Hemlo camp. The properties comprise a total of 20 claims or 169 units located in the historic Thunder Bay Mining District in Northwestern Ontario, just 20 km east of Terrace Bay. The properties are within 90 km of Barrick Gold's world class 25 million ounce Hemlo gold deposit.
QIT.v ~ acquisition of a 100% interest....
Quinto Real Capital Corporation (TSX VENTURE:QIT) ("Quinto" or the "Company") is pleased to announce the acquisition of a 100% interest in three promising gold and base metal properties in the Schreiber-Hemlo camp. The properties comprise a total of 20 claims or 169 units located in the historic Thunder Bay Mining District in Northwestern Ontario, just 20 km east of Terrace Bay. The properties are within 90 km of Barrick Gold's world class 25 million ounce Hemlo gold deposit.
QIT.v ~ acquisition of a 100% interest....
Quinto Real Capital Corporation (TSX VENTURE:QIT) ("Quinto" or the "Company") is pleased to announce the acquisition of a 100% interest in three promising gold and base metal properties in the Schreiber-Hemlo camp. The properties comprise a total of 20 claims or 169 units located in the historic Thunder Bay Mining District in Northwestern Ontario, just 20 km east of Terrace Bay. The properties are within 90 km of Barrick Gold's world class 25 million ounce Hemlo gold deposit.
EVRM ~ Golden Crossed, Trading extremely tight, volume up and fins around the corner. Could be an easy triple bagger from here!!!
http://www.otcmarkets.com/stock/EVRM/short-sales
Current Count:
25,887
EVRM ~ Golden Crossed, Trading extremely tight, volume up and fins around the corner. Could be an easy triple bagger from here!!!
http://www.otcmarkets.com/stock/EVRM/short-sales
Current Count:
25,887
QIT.v ~ The Company holds a 10% interest in TomaGold Corporation's Monster Lake property. In November 2013, IAMGOLD Corporation signed an option agreement with TomaGold to acquire a 50% interest in the Monster Lake, Winchester and Lac à l'eau jaune properties for $17.575 million, including $16 million in exploration and $1.575 million in payments over five years. Once IAMGOLD has acquired its 50% interest, the interests of TomaGold and Quinto will be diluted proportionately such that TomaGold and Quinto hold interests of 45% and 5%, respectively, in the Monster Lake property.
On February 27, 2014, TomaGold announced that IAMGOLD had started drilling on the Monster Lake property. This initial program of at least 6,000 metres of drilling mainly targets the 325 and Mégane zones, but will also test other drill targets identified by the high resolution airborne magnetic survey conducted in early February.
Perisson Petroleum Corporation
Quinto also owns 4,000,000 shares of Perisson Petroleum Corporation, an oil and gas exploration company. On February 10, 2014, Perisson announced an increase in the resources at its VMM-17 oil property in the Middle Magdalena Basin, in the Province of Tolima, central Colombia. A report prepared by Netherlands, Sewell & Associates, Inc. of Dallas, Texas, an independent qualified reserves evaluator, indicates that the VMM-17 property contains an estimated 32 million barrels of classified contingent resources and 350 million barrels of unrisked prospective resources.
QIT.v ~ Low floater with huge upside potential with minimal risk at current PPS. Tightly traded and level II is paper thin!
Capital Quinto Real Corp appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Cash flow in CAD:
In 2013, Capital Quinto Real Corp increased its cash reserves by 43.09%, or 175.61k. Cash Flow from Financing totalled 261.71k or 22,368.38% of revenues. In addition the company used 61.11k for operations while cash used for investing totalled 25.00k
Financial information:
TSX Venture Exchange
Symbol: QIT
Registrar and transfer agent: Computershare
Bank: Scotia Bank
Legal counsel: Seguin Racine, Attorney
Auditors:Petrie Raymond, LLP
Capital structure:
Shares outstanding: 10,849,99
Notice the 50 SMA make a move above the 100 and eyeing that ever soo bullish 200 SMA for the GOLDEN CROSS...ITS COMING MARK THIS!
CHART
I wouldn't even mind a small promo to trap the MM's and then back it up with decent Q results. That would help sustain the run as well and keep the up trend intact!!
We could easily cruise to 01
Would be spectacular. I would be happy with a 50 million day tell the you truth. I see a lot of new faces here, which is a really good sign.
BOOMTOWN; CEO1: Nice board Looks like some heavy hitters on there hanging around. Nice Job!
Had the board marked yesterday and hit you back!
818 for ya
$EVRM ~ Float appears to locked up and MM's have no choice but to let er' run! Technical stand-point, 50 SMA crossed above 100 & 200 day. Anticipating updates from the court proceedings and fins announcement around the corner.
http://www.otcmarkets.com/stock/EVRM/short-sales
Current Count:
25,887
$EVRM ~ Float appears to locked up and MM's have no choice but to let er' run! Technical stand-point, 50 SMA crossed above 100 & 200 day. Anticipating updates from the court proceedings and fins announcement around the corner.
http://www.otcmarkets.com/stock/EVRM/short-sales
Current Count:
25,887
$EVRM ~ Float appears to locked up and MM's have no choice but to let er' run! Technical stand-point, 50 SMA crossed above 100 & 200 day. Anticipating updates from the court proceedings and fins announcement around the corner.
http://www.otcmarkets.com/stock/EVRM/short-sales
Current Count:
25,887
I wonder what the real book orders look for EVRM. Obviously they are hiding the real BIDs. They keep pushing it up while the bid appears to be weak but yet cruises on low volume.
"It is now quite clear why BATS CEO Bill O'Brien was so agitated during the Tuesday's screamfest on CNBC. As The Wall Street Journal's Scott Patterson reports, under pressure from the NYAG, BATS has hurriedly issued a statement correcting the CEO's false comments during the exchange with IEX's Brad Katsuyama. After Katsuyama said "you wanna do this, let's do this" clearly giving him an out, O'Brien stated that BATS priced its trades off 'high-speed' data feeds when in fact they price their trades off"